Results 261 to 270 of about 23,378,967 (385)
Software Application Profile: CaseCohortCoxSurvival-an R package for case-cohort inference for relative hazard and pure risk under the Cox model. [PDF]
Etiévant L, Gail MH.
europepmc +1 more source
Efficient Estimation of the Cox Model with Auxiliary Subgroup Survival Information
Chiung-Yu Huang, J. Qin, H. Tsai
semanticscholar +1 more source
The SNARE protein YKT6 is upregulated in bladder cancer (BLCA), correlating with poor prognosis. YKT6 promotes tumor proliferation and metastasis by activating Wnt/β‐catenin signaling. It recruits Ubiquitin‐Specific Peptidase 7 (USP7) to deubiquitinate and stabilize β‐catenin, enhancing its nuclear accumulation and driving oncogenic gene expression ...
Sheng Tu +16 more
wiley +1 more source
Analyzing Left-Truncated Samples with the Cox Model in the Presence of Missing Covariates. [PDF]
Vazquez O, Locke HM, Xie SX.
europepmc +1 more source
Smoothed estimators of a monotone baseline hazard in the Cox model
Hendrik P. Lopuhaä, Eni Musta
openalex +1 more source
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao +16 more
wiley +1 more source
WebDISCO: a web service for distributed cox model learning without patient-level data sharing
Chia-Lun Lu +6 more
semanticscholar +1 more source
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin +14 more
wiley +1 more source

